Fierce Pharma Biopharma News & Insights
WEBFierce Pharma delivers breaking news and analysis about drug companies, the FDA and the broader pharma industry, including manufacturing, marketing and finance.
Top 20 pharma companies by 2023 revenue - Fierce Pharma
WEBApr 15, 2024 · There were changes at the top and the bottom of last year’s top 20 pharma rankings by revenue. And, in between, Novo Nordisk made a significant leap, jumping five spots propelled by skyrocketing ...
Gilead’s Kite shortens Yescarta manufacturing time with FDA nod
WEBJan 30, 2024 · The manufacturing upgrade comes as Kite works through an important launch for Yescarta as a second-line therapy for large B-cell lymphoma. Last month, the FDA allowed additional patient survival ...
FDA approves Amgen's interchangeable biosimilar of J&J's Stelara
WEBNov 1, 2023 · The agreement also makes it likely that Wezlana will become the first Stelara biosimilar to launch in the U.S. In June, J&J made a similar settlement with Alvotech and Teva to delay the launch of ...
Generic Vyvanse cleared by FDA Amid shortage | Fierce Pharma
WEBAug 30, 2023 · A 100-day supply of the branded drug goes for $1,305, according to Drugs.com. Meanwhile, 30 capsules are priced at around $460. Takeda's Vyvanse shortage emerged after Adderall and its generics ...
The top 10 vaccine companies worldwide - Fierce Pharma
WEBWhat a difference five years—and a global pandemic—can make in reshaping an industry. When Fierce Pharma last published our rankings of the top vaccine players back in 2017, we highlighted the ...
The top 15 blockbuster patent expirations coming this decade
WEBJul 12, 2021 · The biggest names set to face generic pressure in the coming years include the top four of the industry’s best-selling drugs in 2020: Humira, Keytruda, Revlimid and Eliquis. In all, nine of the ...
The top 20 pharma companies by 2021 revenue
WEBApr 12, 2022 · Of the world’s top 20 pharmas ranked by 2021 revenues, 12 had at least 10% growth, including five that saw their sales boom at least 40%. No company pulled in more revenue from COVID products ...
GSK inks another Zantac settlement ahead of trial in California
WEBFeb 1, 2024 · GSK inks another Zantac settlement ahead of trial in California. By Eric Sagonowsky Feb 1, 2024 8:45am. GSK Zantac Marketing. After GSK spent the latter half of 2023 warding off concerns about the ...
Increased demand squeezes supplies of Eli Lilly's Mounjaro—again
WEBJul 26, 2023 · The reason listed for the supply squeeze is a demand increase. Now, supplies of Mounjaro at the 10mg dose are expected to be tight through September 2023. Issues with the 7.5mg, 12.5mg and 15mg ...